Systemic Analyses of Immunophenotypes
Systemic analyses of immunophenotypes of peripheral T cells in non-segmental vitiligo: implication of defective natural killer T cells.
Zhou L, Li K, Shi YL, Hamzavi I, Gao TW, Henderson M, Huggins RH, Agbai O, Mahmoud B, Mi X, Lim HW, Mi QS.
Henry Ford Immunology Program, Henry Ford Hospital, Detroit, MI, USA. email@example.com
Although it is widely believed that non-segmental vitiligo (NSV) results from the autoimmune destruction of melanocytes, a clear understanding of defects in immune tolerance, which mediate this uncontrolled self-reactivity, is still lacking. In the present study, we systemically evaluated circulating regulatory T (Treg) cells, including CD4(+) CD25(+) FoxP3(+) Treg cells and invariant natural killer T (iNKT) cells, as well as naïve and memory CD4(+) and CD8(+) T cells and their cytokine production, in a cohort of 43 progressive NSV patients with race-, gender-, and age-matched healthy controls. We found that the general immunophenotypes of CD4(+) and CD8(+) T cells and the percentage of CD4(+) CD25(+) FoxP3(+) Tregs were comparable between NSV and healthy controls. However, percentages of peripheral iNKT cells were significantly decreased in NSV patients compared to that in healthy controls. Our data confirm the previous notion that the percentage of peripheral CD4(+) CD25(+) FoxP3(+) Tregs remains unaltered in NSV and suggests the involvement of defective iNKT cells in the pathogenesis of NSV.
I support the petition to designate June 25 as Vitiligo World Day and save millions of people worldwide from social isolation and persecution.
What is coming?
NY Vitiligo Community Meeting in September
Our next meeting will be on Thursday, September 21st, at 7PM - 8:30PM on the 11th floor of NYU's Ambulatory Care Center at 240 East 38th Street, between 2nd and 3rd Av...21 September 2017 19:00, 11th floor of NYU's Ambulatory Car...
Vitiligo Advocacy Day at the US Capitol
Save-the-Date for the much anticipated Vitiligo Advocacy Day at the United States Capitol this fall. As many of you know, the Advocacy Committee of the Global Vitilig...04 October 2017 10:00, Washington, DC
How to get insurance coverage for vitiligo treatments?
Most of health insurance companies will initially reject claims for vitiligo doctor visits or phototherapy treatments but with enough efforts you can have a substantia...
What is vitiligo?
Vitiligo (pronounced vit-ill-EYE-go) is a relatively common skin disease characterized by smooth, white, painless spots or patches on various parts of the body. It doe...
Can Scenesse be used for vitiligo treatment?
The drug Scenesse from Clinuvel has been tested in clinical trials in relation vitiligo. Profs. Henry Lim, Mark Lebwohl and coauthors reported (PubMed) results of mult...
Will it spread?
The condition varies from person to person. Some people only get a few small, white patches that progress no further. Other people get bigger white patches that join u...